Kringle Pharma, Inc. (4884) Stock Statistics & Valuation Metrics

Kringle Pharma, Inc. has a market cap or net worth of ¥2.86B. The enterprise value is ¥1.22B.

Kringle Pharma, Inc. has 7,312,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kringle Pharma, Inc.’s return on equity (ROE) is -0.70 and return on invested capital (ROIC) is -46.16%.

The current PE Ratio of Kringle Pharma, Inc. is ―. Kringle Pharma, Inc.’s PEG ratio is -0.26.

In the last 12 months, Kringle Pharma, Inc. had revenue of 72.22M and earned -916.25M in profits. Earnings per share was -133.92.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Kringle Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Kringle Pharma, Inc. upcoming earnings date is Feb 9, 2026, TBA (Confirmed).

Kringle Pharma, Inc. as a current ratio of 18.80, with Debt / Equity ratio of 0.00%

In the past 12 months, Kringle Pharma, Inc. has paid 1.50M in taxes.

Kringle Pharma, Inc. EV to EBITDA ratio is -1.69, with an EV/FCF ratio of 0.00.

Kringle Pharma, Inc. has ¥1.63B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥1.63B billion.

Gross margin is 74.63%, with operating margin of -1259.37%, and net profit margin of -1268.79%.

The average price target for Kringle Pharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―